Lincoln Pharma Standalone June 2024 Net Sales at Rs 147.28 crore, up 8.6% Y-o-Y
August 13, 2024 / 12:11 IST
Reported Standalone quarterly numbers for Lincoln Pharmaceuticals are:Net Sales at Rs 147.28 crore in June 2024 up 8.6% from Rs. 135.62 crore in June 2023.
Quarterly Net Profit at Rs. 23.67 crore in June 2024 up 24.5% from Rs. 19.01 crore in June 2023.
EBITDA stands at Rs. 33.14 crore in June 2024 up 16.65% from Rs. 28.41 crore in June 2023.
Lincoln Pharma EPS has increased to Rs. 11.82 in June 2024 from Rs. 9.49 in June 2023.
| Lincoln Pharma shares closed at 680.35 on August 12, 2024 (NSE) and has given 8.48% returns over the last 6 months and 46.71% over the last 12 months. |
| Lincoln Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'24 | Mar'24 | Jun'23 | | Net Sales/Income from operations | 147.28 | 142.49 | 135.62 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 147.28 | 142.49 | 135.62 | | EXPENDITURE | | Consumption of Raw Materials | 52.75 | 51.89 | 42.70 | | Purchase of Traded Goods | 13.33 | 17.00 | 15.44 | | Increase/Decrease in Stocks | 4.16 | 4.69 | 5.71 | | Power & Fuel | -- | -- | -- | | Employees Cost | 29.02 | 25.05 | 26.47 | | Depreciation | 3.22 | 2.69 | 2.55 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 25.29 | 25.48 | 24.59 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 19.51 | 15.70 | 18.17 | | Other Income | 10.41 | 7.02 | 7.69 | | P/L Before Int., Excpt. Items & Tax | 29.92 | 22.72 | 25.86 | | Interest | 0.44 | 0.50 | 0.41 | | P/L Before Exceptional Items & Tax | 29.48 | 22.22 | 25.45 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 29.48 | 22.22 | 25.45 | | Tax | 5.81 | 3.62 | 6.43 | | P/L After Tax from Ordinary Activities | 23.67 | 18.60 | 19.01 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 23.67 | 18.60 | 19.01 | | Equity Share Capital | 20.03 | 20.03 | 20.03 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 11.82 | 9.28 | 9.49 | | Diluted EPS | 11.82 | 9.28 | 9.49 | | EPS After Extra Ordinary | | Basic EPS | 11.82 | 9.28 | 9.49 | | Diluted EPS | 11.82 | 9.28 | 9.49 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
